Pseudoprogression in a patient with relapsed medulloblastoma after intensive chemotherapy and craniospinal irradiation. A clinical observation and literature review

High-dose chemotherapy (HDCT) with autologous hemopoietic stem cell transplantation (auto-HSCT) is currently an integral part of a standard of care for younger medulloblastoma (MB) patients and MB patients with relapse. As HDCT regimens are characterized by neurotoxicity, it may add to the one of radiation therapy. Therefore, some patients may develop post-irradiation clinical symptoms and MRI changes characteristic for disease progression, pseudoprogression. We report on a case of a 16-year old patient with relapsed MB treated by standard chemotherapy with consequent HDCT and craniospinal irradiation with a boost to cranial fossa posterior. One month after the radiation therapy was finished she developed focal neurological symptoms. The MRI and PET scan have shown cerebellar changes characteristic for disease progression. However, the therаpy with corticosteroids and bevacizumab was able to resolve most clinical symptoms. The MRI scan have also shown evident positive dynamics. Therefore, the clinical course and imaging dynamics corresponded to pseudoprogression. The probability of pseudoprogression may be higher in patients with MB relapse receiving second irradiation and HDCT with auto-HSCT. As we often do not have a morphological proof of relapse, we have to distinguish between progressive disease and pseudoprogression by a complex of clinical course and imaging data.

1. Abbasi A.W., Westerlaan H.E., Holtman G.A., Aden K.M., van Laar P.J., van der Hoorn A. Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol 2018;28(3):401–11. doi: 10.1007/s00062-017-0584-x.

2. Tsang D.S., Murphy E.S., Lucas J.T., Lagiou P., Acharya S., Merchant T.E. Pseudoprogression in pediatric low-grade glioma after irradiation. J Neurooncol 2017;135(2):371–9. doi: 10.1007/s11060-017-2583-9.

3. Naftel R.P., Pollack I.F., Zuccoli G., Deutsch M., Jakacki R.I. Pseudoprogression in low-grade gliomas after radiotherapy. Pediatr Blood Cancer 2015;62(1):35–9. doi: 10.1002/pbc.25179.

4. Negretti L., Blanchard P., Couanet D., Kieff er V., Goma G., Habrand J.L., Dhermain F., Valteau-Couanet D., Grill J., Dufour C. Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: impact on survival. Neuro Oncol 2012;14(11):1413–21. doi: 10.1093/neuonc/nos212.

5. Fouladi M., Chintagumpala M., Laningham F.H., Ashley D., Kellie S.J., Langston J.W., McCluggage C.W., Woo S., Kocak M., Krull K., Kun L.E., Mulhern R.K., Gajjar A. White matter lesions detected by magnetic resonanse imaging after radiotherapy and highdose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 2004;22(22):4551–60. doi: 10.1200/JCO.2004.03.058.

6. Brandsma D., Stalpers L., Taal W., Sminia P., van den Bent M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453–61. doi: 10.1016/S1470-2045(08)70125-6.

7. Foster K.A., Ares W.J., Pollack I.F., Jakacki R.F. Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas. Pediatr Blood Cancer 2015;62(2):240–5. doi: 10.1002/pbc.25277.

8. Miyata K., Hori T., Shimomura Y., Joko M., Takayasu M., Okumura A. Pseudoprogression successfully treated with bevacizumab in a child with spinal pilocytic astrocytoma. Childs Nerv Syst 2018;34(11):2305–8. doi: 10.1007/s00381-018-3841-7.

9. Wetmore C., Herington D., Lin T., Onar-Thomas A., Gajjar A., Merchant T.E. Reirradiation of recurrent medulloblastoma: does clinical benefi t outweight risk of toxicity. Cancer 2014;120(23):3731–7. doi: 10.1002/cncr.28907.

10. Gupta T., Maitre M., Sastri G.J., Krishnatry R., Shirsat N., Epari S., Sahav A., Chinnaswamy G., Patil V., Shetty P., Moiyadi A. Outcomes of salvage reirradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk stratifi cation, and molecular subgrouping. J Neurooncol 2019;144(2):283–91. doi: 10.1007/s11060-019-03225-9.

11. Tsao M.N., Li Y.Q., Lu G., Xu Y., Wong C.S. Upregulation of vascular endothelial growth factor is associated with radiation-induced bloodspinal cord barrier breakdown. J Neuropathol Exp Neurol 1999;58(10):1051–60. doi: 10.1097/00005072-199910000-00003.

12. Wick W., Chinot O.L., Bendszus M., Mason W., Henriksson R., Saran F., Nishikawa R., Revil C., Kerloeguen Y., Cloughesy T. Evaluation of pseudoprogression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 2016;18(10):1434–41. doi: 10.1093/neuonc/now091.

13. Ellingson B.M., Wen P.Y., Cloughesy T.F. Modifi ed criteria for radiagraphic response assessment in glioblastoma clinical trials. Neurotherapeutics 2017;14(2):307–20. doi: 10.1007/s13311-016-0507-6.

14. Wen P.Y., Chang S.M., Van den Bent M.J., Vogelbaum M.A., Macdonald D.R., Lee E.Q. Response Assessment in Neuro-Oncology clinical trials. J Clin Oncol 2017;35(21):2439–49. doi: 10.1200/JCO.2017.72.7511.

15. Nguen T.K., Perry J., Sundaram A.N.E., Detsky J., Maralani P.J., Calabrese E., Das S., Sahgal A. Rescue bevacizumab following symptomatic pseuoprogression of a tectal glioma post-radiotherapy: a case report and review of the literature. J Neurooncol 2019;143(3):475–81. doi: 10.1007/s11060-019-03179-y.

16. Rutkowski S., Cohen B., Finlay J., Luksch R., Ridola V., Valteau-Couanet D., Hara J., Garre M.L., Grill J. Medulloblastoma in young children. Pediatr Blood Cancer 2010;54(4):635–7. doi: 10.1002/pbc.22372.

17. Ridola V., Grill J., Doz F., Gentet J.C., Frappaz D., Raquin M.A., Habrand J.L., Sainte-Rose C., Valtreau-Couanet D., Kalifa C. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007;110(1):156–63. doi: 10.1002/cncr.22761.

18. Chukwueke U.N., Wen P.Y. Use of the Response Assessment in Neurooncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol 2019;8(1):CNS28. doi: 10.2217/cns-2018-0007.

19. Maritaz C., Lemare F., Laplanche A., Demirdjian S., Valteau-Couanet D., Dufour C. High-dose thiotepa-related neurotoxocity and the role of tramadol in children. BMC Cancer 2018;18(1):177. doi: 1186/s12885-018-4090-6.

20. de Wit M.C., de Bruin H.G., Eijkenbom W., Sillevis Smitt P.A., van den Bent M.J. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63(3):535–7. doi: 10.1212/01.wnl.0000133398.11870.9a.

21. Levin V.A., Bidaut L., Hou P., Kumar A.J., Wefel J.S., Bekele B.N., Grewal J., Prabhu S., Loghin M., Gilbert M.R., Jackson E.F. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79(5):1487–95. doi: 10.1016/j.ijrobp.2009.12.061.

22. Xu W., Gao L., Shao A., Zheng J., Zhang J. The performance of 11C-Methionine PET in the diff erential diagnosis of glioma recurrence. Oncotarget 2017;8(53):91030–9. doi: 10.18632/oncotarget.19024.

23. Ellingson B.M., Chung C., Pope W.B., Boxerman J.L., Kaufmann T.J. Pseudoprogression, radionecrosis, infl ammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 2017;134(3):495–504. doi: 10.1007/s11060-017-2375-2.

24. Thust S.C., van den Bent M.J., Smiths M. Pseudoprogression of brain tumors. J Magn Reson Imaging 2018;48(3):571–89. doi: 10.1002/jmri.26171.

25. Spreafi co F., Gandola L., Marchianò A., Simonetti F., Poggi G., Adduci A., Clerici A., Luksch R., Biassoni V., Meazza C., Catania S., Terenziani M., Musumeci R., Fossati-Bellani F., Massimino M. Brain magnetic resonance imaging after high-dose chemotherapy and radiotherapy for childhood brain tumors. Int J Radiat Oncol Biol Phys 2008;70(5):1011–9. doi: 10.1016/j.ijrobp.2007.07.2377.

26. Nudnov N.V., Zheludkova O.G., Mnatsakanova I.V., Sidorova E.V., Podoxenova T.V., Shevtsov A.I. Pseudoprogression in a patient with anaplastic ependymoma after radiation therapy. Meditsinskaya vizualizatsiya = Medical Imaging 2018;22(2):18–24. (In Russ.)

27. Wu C.C., Guo W.Y., Chung W.Y., Wu H.M. Tumor pseudoprogression and true progression following gamma knife radiosurgery for recurrent ependymoma. J Chinese Med Assoc 2016;79(5):292–8. doi: 10.1016/j.jcma.2015.10.005.